TIC10
Product Code:
CDX-T0898
CDX-T0898
Regulatory Status:
RUO
RUO
Shipping:
Ambient
Ambient
Storage:
Short term: +4°C. Long term: -20°C.
Short term: +4°C. Long term: -20°C.
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| CDX-T0898-M100 | 100 mg | £151.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Appearance:
Yellow solid.
CAS:
1616632-77-9
EClass:
32160000
Form:
solid
GHS Symbol:
GHS07
Handling Advice:
Protect from light and moisture.
Hazards:
H302-H315-H319-H335
InChi:
InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
InChiKey:
VLULRUCCHYVXOH-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1616632-77-9. Formula: C24H26N4O. MW: 386.5. TIC10 (ONC201; Dordaviprone), is a first-in-class imipridone anticancer compound widely used in oncology and cancer biology research. It is orally active, stable, and crosses the blood-brain barrier. TIC10 induces tumor cell apoptosis. As a selective antagonist of the dopamine receptor D2 (DRD2) and an agonist of the mitochondrial protease ClpP, leading to disruption of pro-survival signaling and induction of tumor-selective apoptosis. TIC10 is recognized for its ability to activate the TRAIL (TNF-related apoptosis-inducing ligand) pathway while concurrently inhibiting Akt signaling, a central regulator of cancer cell survival and resistance.
MDL:
MFCD28118993
Molecular Formula:
C24H26N4O
Molecular Weight:
386.5
Package Type:
Vial
Precautions:
P261-P264-P280-P312-P337+P313
Product Description:
TIC10 (ONC201; Dordaviprone), is a first-in-class imipridone anticancer compound widely used in oncology and cancer biology research. It is orally active, stable, and crosses the blood-brain barrier. TIC10 induces tumor cell apoptosis. As a selective antagonist of the dopamine receptor D2 (DRD2) and an agonist of the mitochondrial protease ClpP, leading to disruption of pro-survival signaling and induction of tumor-selective apoptosis. TIC10 is recognized for its ability to activate the TRAIL (TNF-related apoptosis-inducing ligand) pathway while concurrently inhibiting Akt signaling, a central regulator of cancer cell survival and resistance.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
CC1=CC=CC=C1CN(C2=O)C3=NCCN3C4=C2CN(CC5=CC=CC=C5)CC4
Solubility Chemicals:
Soluble in DMF (20mg/ml), ethanol (10mg/ml) or DMSO (10mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
Documents
References
[1] J.E. Allen, et al.; Sci. Transl. Med. 5, 171ra117 (2013) | [2] J.E. Allen, et al.; Cancer Res. 75, 1668 (2015) | [3] J. Ishizawa, et al.; Sci. Signal. 9, ra17 (2016) | [4] J.E. Allen, et al.; Oncotarget 7, 74380 (2016) (Review) | [5] V.V. Prabhu, et al.; Neoplasia 22, 725 (2020) (Review) | [6] E.R. Bonner, et al.; Neuro-oncology 23, 542 (2021) | [7] B. Shenoy, et al.; Curr